EGFR and lung carcinoma: Our study also found that MA, acting as a PLA2 inhibitor, significantly inhibited KRAS expression and the downstream ERK pathway in lung cancer cells, suggesting that MA may inhibit KRAS by suppressing PLA2 and overcome the EGFR-TKI resistance in KRAS- mutated lung cancer cells.